Healthcare entity
All 2 tracked stories fall under one category: market-trends. Profound Medical is most often covered alongside Atea Pharmaceuticals, which appears in 1 of these 2 stories. At 5, the average consequence score sits below the same-window beat average of 5.8.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: market-trends. Profound Medical is most often covered alongside Atea Pharmaceuticals, which appears in 1 of these 2 stories. At 5, the average consequence score sits below the same-window beat average of 5.8. Each story carries 3.5 original sources on average, compared with 3.1 for the broader beat in this window. Profound Medical appears in 2 tracked Healthcare stories published from March 5, 2026 through March 6, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 46 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Profound Medical. Shared-story counts are live from our verified record — not editorial picks.
Earnings Release
Companies report Q4 and Full Year 2025 results, signaling a shift to 2026 commercial targets.
Fiscal Year End
Med-tech firms report record system utilization rates for the 2025 calendar year.
Clinical Enrollment
Atea Pharmaceuticals completes enrollment for the Phase 2 Hepatitis C (HCV) trial.
Reimbursement Milestone
Profound Medical receives expanded CPT code coverage for TULSA-PRO in the U.S.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a critical transition period as they navigate commercial launches and reimbursement hurdles. While both firms faced revenue headwinds, Kura's $7 billion AML opportunity and Profound's significant EPS beat underscore a shifting landscape in oncology and incision-less surgery.
Source: themarketsdaily.com · finance.yahoo.com
Atea Pharmaceuticals and Profound Medical headlined a series of Q4 2025 earnings reports, highlighting a shift toward commercial scaling in medical devices and late-stage clinical milestones in biotech. These results underscore a sector-wide focus on capital preservation and high-margin recurring revenue models.
Source: manilatimes.net · manilatimes.net
Profound Medical is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
